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Abstract
Background: The stomach is an infrequent site of breast cancer metastasis. It may prove very
difficult to distinguish a breast cancer metastasis to the stomach from a primary gastric cancer on
the basis of clinical, endoscopic, radiological and histopathological features. It is important to make
this distinction as the basis of treatment for breast cancer metastasis to the stomach is usually with
systemic therapies rather than surgery.
Case presentations: The first patient, a 51 year old woman, developed an apparently localised
signet-ring gastric adenocarcinoma 3 years after treatment for lobular breast cancer with no clinical
evidence of recurrence. Initial gastric biopsies were negative for both oestrogen and progesterone
receptors. Histopathology after a D2 total gastrectomy was reported as T4 N3 Mx.
Immunohistochemistry for Gross Cystic Disease Fluid Protein was positive, suggesting metastatic
breast cancer. The second patient, a 61 year old woman, developed a proximal gastric signet-ring
adenocarcinoma 14 years after initial treatment for breast cancer which had subsequently recurred
with bony and pleural metastases. In this case, initial gastric biopsies were positive for both
oestrogen and progesterone receptors; subsequent investigations revealed widespread metastases
and surgery was avoided.
Conclusion: In patients with a history of breast cancer, a high index of suspicion for potential
breast cancer metastasis to the stomach should be maintained when new gastrointestinal
symptoms develop or an apparent primary gastric cancer is diagnosed. Complete histopathological
and immunohistochemical analysis of the gastric biopsies and comparison with the original breast
cancer pathology is important.
Background
Metastatic spread to the upper gastrointestinal tract is
infrequently reported with cancers of the breast, lung, kid-
ney and malignant melanoma [1]. The most common
sites of breast cancer metastasis are the skeleton, lungs and
the liver; the stomach, peritoneum, colon, retroperito-
neum and the small bowel have all been reported as
potential sites of metastatic involvement [2]. Metastatic
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spread to the stomach may occur many years after the ini-
tial treatment for breast cancer. It may prove very difficult
to distinguish from a primary gastric cancer on clinical,
endoscopic, radiological and histopathological features
[3-5]. However, it is important to make this distinction as
the basis of treatment for breast cancer metastasis to the
stomach is usually with systemic therapies rather than sur-
gery [6,7].
The authors present two cases of breast cancer metastasis
to the stomach, both of which were initially considered to
represent primary gastric cancer. The authors also review
current literature with a particular emphasis on the utility
of immunohistochemistry in differentiating between pri-
mary gastric cancer and gastric metastasis from breast can-
cer.
Case Presentations
Patient 1
A fifty-one year old woman presented with weight loss
and vague epigastric pain. Three years previously, she had
undergone a wide local excision and axillary dissection for
a right sided breast lump. Postoperative histology showed
a completely excised grade II invasive carcinoma (T2)
with associated intermediate grade DCIS. On immunohis-
tochemistry, the tumour was found to be positive for both
oestrogen and progesterone receptors but negative for E-
cadherin, suggesting a predominantly lobular tumour
type; all eight excised lymph nodes were clear of metas-
tases (N0). She had subsequently received adjuvant radio-
therapy to the breast. As she was unable to tolerate either
tamoxifen or anastrozole due to side effects (persistent
hot flushes), surgical oophorectomy had been performed.
She required tibolone to treat menopausal symptoms. She
had been regularly reviewed in breast clinic without any
clinical evidence of recurrence.
She was initially investigated with an upper gastrointesti-
nal endoscopy. This demonstrated only small antral pol-
yps, which were biopsied (Figure 1). Histology revealed
gastric mucosa infiltrated by poorly differentiated adeno-
carcinoma of a signet-ring pattern, with immunostaining
negative for oestrogen, progesterone receptors and Her-2.
Due to the unexpected nature of these findings, a further
upper gastrointestinal endoscopy was performed with
repeat biopsies from both proximal and distal stomach
which, again, were consistent with signet-ring type adeno-
carcinoma (Figure 2). Computed tomography (CT) could
not define a definite primary gastric cancer; there was no
evidence of lymph node or metastatic spread (Tx N0 M0).
The patient was counselled for radical curative surgery in
view of an apparent localised primary gastric cancer. A D2
total gastrectomy with Roux-en-Y reconstruction was per-
formed and the patient made an uneventful postoperative
recovery. Post operative histology revealed a poorly differ-
entiated adenocarcinoma of the stomach, invading into
the duodenum, with 40 out of 41 lymph nodes involved
(pT4 N3 Mx). Immunohistochemistry performed on the
stomach and lymph nodes was positive for CK7 and
GCDFP (Gross Cystic Disease Fluid Protein) (Figure 3)
and negative for CK20, E-cadherin and Her-2. The tumour
in the lymph nodes, but not the stomach, was strongly
positive for both oestrogen and progesterone receptors.
Consequently, the diagnosis was revised to metastatic
breast cancer. The patient was considered for further hor-
monal therapy. Subsequently she developed widespread
bony metastases. She is currently receiving bisphospho-
nates and palliative care.
Patient 2
A sixty-one year old woman had undergone a mastectomy
and axillary dissection for a left sided breast cancer four-
teen years previously. Postoperative histology revealed a
grade III 4 × 2 × 2 cm infiltrating lobular carcinoma; the
tumour was positive for both oestrogen and progesterone
receptors but negative for E-cadherin. Fourteen out of fif-
teen sampled lymph nodes contained metastases. The
Endoscopic view of fundal polyp in patient 1, biopsies of  which confirmed signet-ring adenocarcinoma Figure 2
Endoscopic view of fundal polyp in patient 1, biopsies of 
which confirmed signet-ring adenocarcinoma.
Endoscopic view of antral polyps in patient 1, biopsies of  which confirmed signet-ring adenocarcinoma Figure 1
Endoscopic view of antral polyps in patient 1, biopsies of 
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patient then received adjuvant chemotherapy, radiother-
apy to the breast and five years' treatment with tamoxifen.
She remained disease free on follow up until one year ago
when she was diagnosed with bony metastases and a
malignant pleural effusion. This was treated with paclit-
axel chemotherapy, followed by letrozole and ibandro-
nate, with symptomatic improvement and apparent
disease remission.
Nine months after this recurrence she presented with pro-
gressive dysphagia and weight loss. An upper gastrointes-
tinal endoscopy revealed a tumour arising from the
gastro-oesophageal junction and occupying the lesser
curve of the anterior gastric wall. Biopsies revealed a
poorly differentiated adenocarcinoma of signet ring cell
type. CT showed an extensive gastric cancer just below the
oesophagogastric junction without any obvious lymph
node or metastatic spread; this was staged as T3 N0 M0
(Figure 4).
She was referred to our unit for a surgical opinion. She was
planned for a staging laparoscopy but, before this could
be performed, she developed a left sided upward gaze. CT
scan of the brain showed a left retro-orbital space occupy-
ing lesion consistent with a metastasis. Immunohisto-
chemistry on the biopsies from the stomach became
available at this stage and were positive for both oestrogen
and progesterone receptors (CK7, ER and PR positive;
CK20 and Her-2 negative), consistent with metastatic
breast carcinoma (Figure 5). Further surgical intervention
was avoided and the patient has received further chemo-
therapy and radiotherapy to her brain.
Discussion
Both of the patients in this report were initially diagnosed
with an apparent primary gastric cancer. Ultimately this
diagnosis was revised to metastatic breast cancer, but only
after surgery had been performed in patient 1. The inci-
dence of breast cancer metastasis to the stomach in long
term follow up and post mortem studies has been esti-
mated at 2–18% [3,6,8-11]. This may occur many years
after the diagnosis of the primary breast lesion and, in 90
– 94% of patients, there will be concurrent sites of breast
Gastric biopsy from patient 2 is infiltrated by a poorly differ- entiated adenocarcinoma with signet ring cell morphology  (panel A) Figure 5
Gastric biopsy from patient 2 is infiltrated by a poorly differ-
entiated adenocarcinoma with signet ring cell morphology 
(panel A). Immunohistochemistry showing positive staining 
for CK7 (panel B), oestrogen receptor (panel C) and proges-
terone receptor (panel D).
An invasive adenocarcinoma is present in the gastrectomy  specimen from patient 1 Figure 3
An invasive adenocarcinoma is present in the gastrectomy 
specimen from patient 1. Numerous signet ring cells are seen 
in the gastric wall (panel A). Carcinoma cells are immunohis-
tochemically positive for CK7 (panel B) and gross cystic dis-
ease fluid protein (GCDFP) (panel C). Metastatic carcinoma 
cells in the lymph node (panel D) are also positive for 
GCDFP (insert).
CT abdomen with oral contrast in patient 2 demonstrating  thickening below the oesophagogastric junction (indicated by  arrow) and residual right sided pleural effusion Figure 4
CT abdomen with oral contrast in patient 2 demonstrating 
thickening below the oesophagogastric junction (indicated by 
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cancer metastasis [6,7]. Patient 2 had been treated for
recurrent breast cancer prior to her presentation with a
gastric tumour.
The clinical presentation of a breast cancer metastasis to
the stomach is often indistinguishable from primary gas-
tric cancer, as seen in the two patients in this report. Com-
mon symptoms include dyspepsia, anorexia, epigastric
pain, early satiety, vomiting and bleeding. The most com-
mon pattern of breast cancer metastasis to the stomach is
a linitis plastica with diffuse infiltration of the submucosa
and muscularis propria; less commonly, discrete nodules
or external compression may occur [7]. Madeya and Bor-
sch reported that 73% of patients with gastric metastases
had diffuse intramural infiltration imitating linitis plas-
tica [12]. Diffuse infiltration of the stomach is characteris-
tic of metastases from invasive lobular carcinoma: Taal et
al reported that 83% of patients with gastric metastasis
had lobular breast carcinoma as the primary pathology
[6]. Patient 1 had a linitis plastica type pattern whereas
patient 2 had a discrete proximal gastric lesion.
A high index of suspicion for metastatic breast cancer
should be maintained when a patient develops gastric
pathology with a history of breast cancer. Endoscopic,
radiological and histological evaluation is essential to dis-
criminate between primary gastric cancer and breast can-
cer metastasis to the stomach. Macroscopic endoscopic
findings are usually unhelpful in identifying the underly-
ing pathology. Since metastatic gastric infiltration is fre-
quently limited to the submucosa and seromuscular layer,
endoscopic evaluation may be normal in 50% of cases or
only show discrete mucosal abnormalities indistinguisha-
ble from other tumours or benign disease [13]. Radiolog-
ical findings on computed tomography or barium studies
include encasement of the whole stomach as seen in lini-
tis plastica, multiple lesions of the stomach or extrinsic
lesions of the gastric wall [4]. Deep and extensive biopsies
should be performed at endoscopy. Their histology
should be compared with the primary breast cancer
pathology as the histologic picture may be similar. How-
ever, lobular carcinoma of the breast may produce a signet
ring morphology which can be confused with a primary
signet ring or diffuse-type gastric adenocarcinoma [7].
Both of the patients in this study had been previously
treated for lobular breast cancer.
Detailed immunohistochemical analysis may be the only
consistent method for differentiating between metastatic
and primary gastric carcinoma. Although oestrogen and
progesterone receptor positivity in the gastric biopsies
suggest breast cancer metastasis to the stomach, it is worth
noting that oestrogen and progesterone receptor positivity
have been reported in 32% and 12% of patients with pri-
mary gastric cancer [14]. However, these findings are
based upon studies using first-generation antibodies
against Oestrogen receptor β (ERβ) which are no longer
used in standard practice. Taal et al investigated whether
immunohistochemical detection with second-generation
antibodies against Oestrogen receptor α (ERα) can be
used to diagnose gastric metastasis of breast carcinoma
[15]. In their study none of the primary gastric carcinomas
expressed ERα. Moreover, no cases with an ER- primary
breast carcinoma and an ERα+ carcinoma in a gastric
biopsy specimen were found. Therefore they concluded
that ERα expression can be reliably used to diagnose gas-
tric metastasis of breast carcinoma. They also investigated
if the expression pattern of E-cadherin could be of help in
the differential diagnosis of primary gastric cancer versus
metastatic breast carcinoma. In their study absence of E-
cadherin staining was significantly related to metastatic
breast carcinoma. It appears that the absence of E-cad-
herin expression in an adenocarcinoma in a gastric biopsy
should raise the possibility of metastatic breast carcinoma
and ERα positivity can be reliably used to diagnose gastric
metastasis of breast carcinoma.
The absence of positive oestrogen and progesterone recep-
tors in patient 1's gastric biopsies led to the initial assump-
tion that this was a primary gastric cancer. Positive
monoclonal staining with GCDFP-15 (gross cystic disease
fluid protein-15) has been found to be a sensitive (55–
76%) and specific (95–100%) marker to correctly identify
a malignant lesion as metastatic breast carcinoma [5,16-
21]. This marker is a monoclonal antibody of gross cystic
disease fluid protein-15 (GCDFP-15) which is detected in
macroscopic breast cyst fluid and in the plasma of patients
with breast cancer [22,23]. There is an excellent correla-
tion between GCDFP-15 positivity and the origin of a
metastatic breast adenocarcinoma [17]. Wick demon-
strated reactivity for GCDFP-15 in 76 of 105 breast carci-
nomas (72%) [16]. The diagnosis of metastatic breast
cancer in patient 1 was eventually confirmed on the basis
of GCDFP immunohistochemistry.
In common with other sites of metastatic breast cancer,
breast cancer metastasis to the stomach should be treated
systemically [7]. The choice of systemic treatment is based
upon presenting symptoms, age, general performance sta-
tus, receptor status and previous systemic treatments. The
response rate to chemotherapy and hormonal therapy var-
ies: the median survival in two small series of patients
receiving systemic treatment for breast cancer metastasis
to the stomach and gastrointestinal tract varied between
10 and 28 months [6,24]. In a series of 51 patients with
gastric metastases from the breast, hormonal therapy
(27%) was performed almost as frequently as chemother-
apy (33%) [7]. The options for hormonal therapy
included tamoxifen, oophorectomy or progesterone as
first-line treatment, and aminogluthetimide, androgensWorld Journal of Surgical Oncology 2007, 5:75 http://www.wjso.com/content/5/1/75
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or prednisolone as second line treatment. New anti-hor-
monal drugs also include aromatase inhibitors and
GNRH analogues in pre-menopausal patients. Although
combination cyclophosphamide, methotrexate and 5-
fluorouracil (CMF) tends not to be used in the metastatic
setting, new anti-neoplastic drugs are now available and
include taxanes, capecitabine and trastzumab if c-erbB2 is
positive.
One study has shown that a partial remission with a clear
palliative effect can be obtained in only 46% of patients
receiving systemic therapy with no obvious difference in
response rates between hormonal treatment and chemo-
therapy. It is worth noting that symptomatic treatments
alone such as acid reduction could only be performed in
20% of the patients in this study due to their poor general
condition or extensive prior treatment [7]. McLemore et al
reported a median overall survival after diagnosis of 28
months in 73 patients with breast cancer metastasis to the
gastrointestinal tract [24]: whilst advanced age at diagno-
sis and gastric metastasis had a negative effect on survival,
treatment with systemic chemotherapy or tamoxifen had
a positive effect on survival. It is worth noting that there is
a low response rate to chemotherapy in invasive lobular
carcinoma patients which must be must taken into con-
sideration when choosing the most appropriate treatment
[25].
The complications of breast cancer metastasis to the stom-
ach can be managed in a similar manner to primary gastric
cancer: endoluminal stents can be used for gastric outlet
obstruction; bleeding may be controlled by endoscopic or
endovascular therapy [26-31]. Although surgical resection
has been considered in selected patients, the role of sur-
gery is usually limited as the gastric metastasis reflects sys-
temic disease [6,32]. Palliative surgery has not been
shown to affect overall survival [24]. Surgery should be
limited to palliative bypass in those patients where less
invasive measures fail to palliate their gastric outlet
obstruction.
Conclusion
In patients with a history of breast cancer, a high index of
suspicion for potential breast cancer metastasis to the
stomach should be maintained when new gastrointestinal
symptoms develop or an apparent primary gastric cancer
is diagnosed. Complete histopathological and immuno-
histochemical analysis of the gastric biopsies and compar-
ison with the original breast carcinoma pathology is
essential to support the diagnosis of metastatic breast car-
cinoma. Appropriate systemic treatment for metastatic
breast carcinoma is the preferred treatment.
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